Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial
Titel:
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial
Auteur:
Kang, Yoon-Koo Ryu, Min-Hee Di Bartolomeo, Maria Chau, Ian Yoon, Harry Kim, Jong Gwang Lee, Keun-Wook Oh, Sang Chul Takashima, Atsuo Kryzhanivska, Anna Chao, Yee Evesque, Ludovic Schenker, Michael McGinn, Arlo Zhao, Yufan Lee, Jennifer Wyrwicz, Lucjan Boku, Narikazu